Internal cardiac defibrillation: histopathology and temporal stability of defibrillation energy requirements.

The automatic implantable cardioverter/defibrillator is tested intraoperatively to ensure effectiveness by performing a number of induced fibrillation-defibrillation trials. The temporal stability of defibrillation energy requirements and the histopathologic effects of multiple defibrillating shocks were studied in 12 dogs chronically instrumented with an internal spring-patch lead system identical to that used in humans. Dogs were studied on days 1, 11, 18, 25 and 32. Data were analyzed by logistic regression and the energy required for 50% (E50) and 80% (E80) success was compared. On day 32 the dogs were killed and the heart was removed for gross and microscopic pathologic examination. There was a significant decrease in energy requirements from day 1 to day 11, as the E50 decreased from 6.9 +/- 4.5 to 4.9 +/- 2.5 J (p less than 0.02) and the E80 decreased from 8.5 +/- 5.2 to 6.1 +/- 3.4 J (p less than 0.02). The energy requirements then remained stable over the remainder of the experiment. The dogs were administered 209 +/- 18 shocks (range 1 to 24 J) for a total cumulative dose of 1,524 +/- 571 J. In all cases, both grossly and microscopically, there was no evidence of pathologic changes in the myocardium or coronary vessels. In all cases there was a fibrous plaque beneath the patch electrodes, at times containing an area of patchy hemorrhage; in a single specimen a mixed inflammatory infiltrate accompanied the hemorrhage. Endothelialization of the spring electrode with mild right atrial endocardial fibrosis was also observed.(ABSTRACT TRUNCATED AT 250 WORDS)

Lidocaine causes a reversible, concentration-dependent increase in defibrillation energy requirements.

To investigate the influence of lidocaine on the energy requirements for internal defibrillation, lidocaine (n = 8) or saline solution (n = 12) was administered by intravenous infusion to 20 pentobarbital-anesthetized dogs, and the likelihood of successful defibrillation was examined at various shock energy levels before and after treatment. After lidocaine administration to a mean steady state concentration of 5.6 +/- 2.7 micrograms/ml, the mean energy required to achieve 50 and 90% success in defibrillation (E50 and E90) increased by 61.1 +/- 34.1% (mean +/- SD, p less than 0.005) and 47.1 +/- 28.6% (p less than 0.005), respectively. The steady state log lidocaine concentration correlated positively with the observed increase in E50 (r = 0.887, p less than 0.01) over a concentration range from 1.95 to 9.8 micrograms/ml. In a related experiment, lidocaine infusion was administered to five dogs and then abruptly discontinued. At energy levels achieving a mean 90.0 +/- 10.0% success in defibrillation before treatment, only 43.3 +/- 23.4% success was achieved after 60 minutes of the lidocaine infusion (p less than 0.01) at a mean plasma concentration of 8.4 +/- 2.1 micrograms/ml. The percent of successful defibrillations returned to baseline value (92.0 +/- 18.0%, p less than 0.01) after drug washout at a time when mean lidocaine concentration had declined to 1.8 +/- 0.5 microgram/ml. Lidocaine causes a reversible, concentration-dependent increase in the energy requirements for successful defibrillation; recommendations to administer lidocaine to patients with ventricular fibrillation resistant to defibrillation may need to be reviewed.

Comparison of defibrillation efficacy in humans using a new catheter and superior vena cava spring-left ventricular patch electrodes.

The automatic implantable cardioverter-defibrillator currently utilizes an electrode system that requires a major operation for implantation. Effective defibrillation using an implantable cardioverter-defibrillator catheter positioned transvenously would eliminate the morbidity associated with such surgery. Fifteen patients undergoing defibrillator implantation were studied to compare the efficacy of the catheter with that of the superior vena cava spring (6.7 cm2, anode)-left ventricular patch (13.5 cm2, cathode) electrode system using truncated exponential waveforms with 60% tilt. The catheter is 11F in diameter and tripolar. A distal platinum-iridium tip used for pacing was separated by 4 mm from a middle 4.3 cm2 platinum electrode; these were positioned at the right ventricular apex. The proximal 8.5 cm2 platinum electrode was situated at the superior vena cava-right atrial junction. Defibrillation was performed using the middle (cathode) and proximal (anode) electrodes. Ventricular fibrillation was induced by alternating current six times, and defibrillation shocks of 1, 5, 10, 15, 20 or 25 J were given in random order, first using the catheter and then the spring-patch system. Rescue shocks of higher energy were given if there was failure. Although very low energy levels appeared to be slightly more efficacious when using the spring-patch system, there was no statistically significant difference between the electrode systems for any of the energies tested. Permanent implantation of the catheter would have been suitable in 45% of the patients, as compared with 54% of patients with the spring-patch system (p = NS).(ABSTRACT TRUNCATED AT 250 WORDS)

Implantable cardioverter defibrillator: Ventritex Cadence.

The Ventritex Cadence Model V-100 Tiered Therapy Defibrillator is a third generation antitachyarrhythmia device currently completing clinical trials in the United States. The implantable pulse generator is capable of high energy defibrillation, low energy cardioversion, as well as antitachycardia and bradycardia pacing. In addition, this microprocessor controlled device can deliver monophasic or biphasic defibrillation/cardioversion shocks, is noncommitted to deliver shock therapy after initiating charging for defibrillation or cardioversion therapy, and can store electrograms of spontaneous tachyarrhythmia episodes. These expanded device capabilities should improve therapy efficacy and patient management, and represent a major advance in the treatment of patients with ventricular tachyarrhythmias.

Effects of acute intravenous and chronic oral amiodarone on defibrillation energy requirements.

Amiodarone is commonly used with the automatic implantable defibrillator to treat recurrent ventricular tachyarrhythmias. The effects of acute intravenous and chronic oral amiodarone on the energy requirements for successful defibrillation were evaluated in 12 dogs chronically instrumented with right atrial spring and left ventricular patch defibrillation electrodes. Multiple shocks of varying energy were applied in balanced random order to construct curves of percent successful defibrillation vs energy (DF curves) on each test day. Dogs were studied on days 1, 11, 18, 25, and 32. On day 11, DF curves were determined before and after infusing saline (n = 6) or amiodarone (n = 6), 10 mg/kg loading and 0.33 mg/kg/min maintenance doses. Dogs administered intravenous amiodarone were continued on oral drug (300 mg twice daily) for the remainder of the study. Data were analyzed by logistic regression and the energy required for 50% (E50) and 80% (E80) successful defibrillation were compared. Differences between controls and animals receiving chronic oral amiodarone were not significant on any day. After acute intravenous infusion, dogs given amiodarone had a 21.7 +/- 12.8% decrease in E50 (p less than 0.01) and a 19.7 +/- 17.8% decrease in E80 (p less than 0.05), while controls had an 11.4 +/- 30.5% increase (p = NS) in E50 and 6.30 +/- 30.5 increase in E80 (p = NS). It is concluded that the energy required for successful defibrillation is decreased by acute intravenous amiodarone, while chronic oral administration has no significant effect.

Improved internal defibrillation efficacy with a biphasic waveform.

Clinically available automatic implantable defibrillators use a monophasic truncated exponential waveform shock; after delivery the charge remaining on the device's capacitors is "dumped" internally and wasted. The efficacy of a monophasic and biphasic truncated exponential defibrillation waveform produced by a single capacitor discharge was compared in seven closed-chest, pentobarbital-anesthetized dogs. Defibrillation leads consisted of a new deployable intrapericardial electrode system. The monophasic waveform was positive and 6 msec in duration. The biphasic waveform had a positive phase identical to that of the monophasic waveform and a negative phase of equal duration with its initial voltage equal to 50% of the final voltage of the positive phase. Defibrillation shocks of varying initial voltage were delivered to construct curves of the percentage of successful defibrillation versus initial voltage and delivered energy, and the voltage and energy required for 50% (V50 and E50, respectively) and 80% (V80 and E80, respectively) success were compared. The biphasic waveform had significantly lower initial voltage (V50: 194 +/- 48 volts vs 227 +/- 48 volts, p less than 0.001; V80: 217 +/- 55 volts vs 256 +/- 66 volts, p less than 0.02) and energy (E50: 2.7 +/- 1.3 joules vs 3.4 +/- 1.5 joules, p less than 0.01; E80: 3.4 +/- 1.6 joules vs 4.3 +/- 2.2 joules, p less than 0.05) requirements than the monophasic waveform. It is concluded that a biphasic waveform produced by a single discharge that uses the "free" energy remaining on the capacitors significantly reduces the initial voltage and energy requirements for successful defibrillation and may improve the efficacy of future automatic implantable defibrillators.

Sequential pulse internal defibrillation: is there an advantage to "switched" current pathways?

Sequential pulse internal defibrillation delivered via orthogonal current pathways has been postulated to improve defibrillation efficacy. The efficacy of twin truncated exponential sequential shocks was compared in four different defibrillation electrode configurations in six pentobarbital-anesthetized, open-chest dogs. Lead systems consisted of the conventional single current pathway spring-patch and patch-patch electrode configurations, as well as a multiple patch lead configuration, which utilized either a single (multiple patch-unswitched) or two different (multiple patch-switched) current pathways. Curves of percent successful defibrillation versus initial voltage and energy were constructed and the data were analyzed by logistic regression. The energy and initial voltage required for 50% successful defibrillation (E50 and V50, respectively) for each lead system were then compared. The E50 for the multiple patch-unswitched and switched lead systems (4.3 +/- 1.5 J and 4.6 +/- 1.7 J, respectively) were significantly lower than for the spring-patch (9.0 +/- 3.1 J; p less than .005) and patch-patch (6.6 +/- 1.2 J; p less than .005) lead systems. In addition, the V50 for the multiple patch-unswitched lead configuration (270.6 +/- 48.4 V) was significantly lower than that of all other lead systems (p less than .005). Therefore lead configurations utilizing multiple patch electrodes improve defibrillation efficacy over conventional lead systems, but there is no advantage to "switched" current pathways.

The effect of electrode size on transvenous defibrillation energy requirements: a prospective evaluation.

Recent technological advances have resulted in high success rates for implantation of nonthoracotomy defibrillation lead systems. Further decreases in defibrillator size, facilitating pectoral placement, will depend in part on lowering defibrillation energy requirements. The purpose of this study was to determine if endocardial defibrillation energy requirements are influenced by electrode size. Thirteen adult mongrel dogs were studied under general anesthesia. A 9 Fr integrated bipolar pace/sense/defibrillation electrode (cathode) was positioned transvenously at the RV apex. The second defibrillation electrode (anode) was positioned at the junction of the RA and SVC. Two diameters of the proximal electrode, 7 Fr and 11 Fr, were sequentially tested in random order in each animal. The DFT for each electrode was determined using a 50-V up-down method. Energy, leading edge voltage, and current, current distribution, and total resistance were measured. The mean defibrillation voltage threshold with the 11 Fr proximal electrode was significantly less than with the 7 Fr proximal electrode (551.1 +/- 76.5 V vs 588.5 +/- 54.6 V, P < 0.01). Similarly, the mean DFT with the 11 Fr electrode was less than with the 7 Fr electrode (20.7 +/- 5.7 J vs 23.3 +/- 4.4 J, P < 0.01). Lower DFTs were found using the larger electrode in 11 of the 13 animals studied. However, there was no difference in defibrillation lead impedance between the two electrode systems. Endocardial defibrillation energy requirements may be lowered with a larger diameter proximal electrode. The mechanism by which this occurs may be due to a more even distribution of current gradients with the larger electrode. Determination of the optimal electrode size requires evaluation in humans, as this may allow further reduction in defibrillation energy requirements and defibrillator size.

The relationship between successful defibrillation and delivered energy in open-chest dogs: reappraisal of the "defibrillation threshold" concept.

The traditional assessment of the energy required for successful ventricular defibrillation involves the measurement of a "defibrillation threshold" (DFT), implying a clear-cut distinction between effective and ineffective energies. We examined the relationship between delivered energy and the likelihood of successful defibrillation in 10 open-chest pentobarbital anesthetized dogs, with the use of an internal spring/patch electrode system. An initial DFT was determined by decreasing the energy discharged until a failure first occurred (10.3 +/- 3.4 J). Six energy levels in 1 to 2 J increments were then selected surrounding this value and each was administered eight times in balanced random order (total 48 trials). The relationship between energy and percent success in defibrillation exhibited a shallow slope, with a gradual increase in success from 0% to 100% over several energy increments. The initial DFTs showed actual success rates varying from 25% to 87.5% (mean 71 +/- 26%). The results were fitted to a sigmoidal dose-response curve by logistic regression analysis and the energy associated with 50% success (E50) and 80% success (E80) was determined, as no single value for DFT could be defined in any animal. In 12 other dogs, a defibrillation curve was similarly constructed at baseline and was repeated after 90 minutes. No significant change in E50 (5.0 +/- 2.1 J vs 5.2 +/- 2.7 J) or E80 (6.3 +/- 2.5 J vs 6.6 +/- 3.2 J) was observed.(ABSTRACT TRUNCATED AT 250 WORDS)

Effects of encainide and its metabolites on energy requirements for defibrillation.

Encainide, a class IC antiarrhythmic agent, has been associated with proarrhythmic responses of ventricular tachycardia and fibrillation requiring defibrillation in patients. We examined the short-term effects of intravenous encainide and its two major metabolites, O-demethyl-encainide (ODE) and 3-methoxy-ODE (MODE), on the energy requirements for successful defibrillation in 25 pentobarbital-anesthetized, open-chest dogs. Truncated exponential (60% tilt) defibrillation shocks were administered through right atrial spring and left ventricular epicardial patch electrodes identical to those used in man with the automatic implantable defibrillator. At baseline multiple shocks of varying energy were applied to construct curves of percent successful defibrillation as a function of energy (DF curves) for each animal. Encainide, ODE, or MODE was then infused in loading and maintenance doses to achieve QRS widening of 20% to 50%. Saline was administered to animals serving as controls. Determination of the DF curve was repeated, after which the infusion was discontinued. After 1 hr washout period, an additional DF curve was constructed. The data were analyzed by logistic regression, and the energies required for 50% successful defibrillation (E50) were compared. No significant differences existed between the four groups in body or heart weight, extent of QRS widening, or baseline E50 values. After administration of encainide and ODE, the E50 increased by 129 +/- 43% (p less than .001) and 76 +/- 34% (p less than .005), respectively. Return of E50 toward baseline was observed after the washout periods in both groups (p less than .025), demonstrating the reversibility of the drugs' effects.(ABSTRACT TRUNCATED AT 250 WORDS)

Effect of quinidine and bretylium on defibrillation energy requirements.

We examined the effect of bretylium and quinidine on the energy requirements for internal defibrillation in 14 pentobarbital-anesthetized dogs. Bretylium, 6 or 10 mg/kg (n = 6), did not affect the relation between energy and the likelihood of successful defibrillation. The mean energy required to achieve 50% success (E50) or 90% success (E90) in defibrillation was not significantly altered; E50 was 5.3 +/- 1.9 J (X +/- s.d) before and 6.1 +/- 3.5 J after bretylium (n.s.), and E90 was 7.2 +/- 2.1 J before and 8.6 +/- 3.3 J after drug (n.s.). Quinidine was administered in a series of two loading and maintenance infusions to achieve mean plasma concentrations of 2.4 +/- 0.63 and 2.95 +/- 0.88 microgram/ml, respectively (n = 8). No significant effect on defibrillation energy requirement was observed; mean E50 before and after treatment was 6.3 +/- 3.3 J and 6.2 +/- 2.9 J, respectively, and mean E90 was 8.3 +/- 4.4 J and 8.3 +/- 4.1 J, respectively. Similarly, saline administration to control dogs (n = 12) resulted in no change in E50 or E90. At concentrations or doses similar to those in patients with serious arrhythmias, neither quinidine nor bretylium appears to have consistent effects on the energy requirements for internal defibrillation in our dog model.

Predictors of device activation for ventricular arrhythmias and survival in patients with implantable pacemakers/defibrillators. CADENCE Investigators.

Predictors of survival and arrhythmia recurrence for patients with implanted defibrillators have been reported but patients with sustained, well-tolerated ventricular tachycardia were often excluded from these trials. Arrhythmia recurrence and survival in populations including these patients have been less well studied. The purpose of the present study was to examine predictors of spontaneous ventricular arrhythmias and mortality in patients who received a tiered therapy antitachycardia pacemaker/defibrillator for ventricular tachycardia, fibrillation, or both. Three hundred thirty-seven patients who received a Ventritex CADENCE tiered therapy antitachycardia device at one of 19 participating centers between July 11, 1989 and March 4, 1991 are included in this retrospective analysis. Diagnostic summary data and stored electrograms telemetered from the implanted device were assessed to determine characteristics of recurrent arrhythmias. Mean follow-up was 360 +/- 10 (SEM) days. Thirty-three patients died during follow-up. At least one recurrent ventricular arrhythmia was observed in 205 patients (61%). A total of 7,539 episodes were observed with a mean of 37 +/- 5 per patient. Patients with recurrent ventricular arrhythmias were slightly but significantly older (64 +/- 0.7 vs 59 +/- 1.2 years; P < 0.001) but were not distinguished by gender or underlying structural disease. Patients whose presenting arrhythmia was monomorphic ventricular tachycardia were more likely to experience recurrent ventricular arrhythmias (69% recurrence rate) than patients presenting with ventricular fibrillation or polymorphic ventricular tachycardia (46% recurrence rate; P < 0.001). Cycle length of spontaneous tachycardia was also a predictor of arrhythmia recurrence. Patients having slower ventricular arrhythmias were less likely to remain recurrence free. Mean left ventricular ejection fraction was similar for patients with and without recurrences. Younger age and absence of arrhythmia recurrence but not presenting arrhythmia were predictors of survival. We conclude that age and presentation with monomorphic ventricular tachycardia are important predictors of arrhythmia recurrence for this patient population. Exclusion of patients with monomorphic ventricular tachycardia underestimates the rate of recurrent ventricular arrhythmias and utilization of device therapy.

Importance of electrode conductive surface area and edge effects on ventricular defibrillation efficacy.

INTRODUCTION: The role of edge effects and electrode surface area of the right ventricular (RV) transvenous lead (TVL) on defibrillation efficacy is unknown. METHODS AND RESULTS: Defibrillation threshold (DFT) testing was conducted randomly in 12 dogs using ring electrode leads in an RV/SVC (superior vena cava) or RV/SVC/patch system. The leads (RV-4, RV-8t, RV-8, RV-15) had electrode surface areas of 20%, 20%, 40%, and 70%, respectively. A computer model predicted the magnitude of electrode surface current (RV-8t > RV-4 > RV-8 > RV-15) and the potential distribution (PD) at four sites: electrode surface (site a) and at 2 mm (b), 4 mm (c), and 8 mm (d) away from the surface. Despite different near-field PDs (sites a, b, c), PDs were nearly identical at site d. Resistance decreased as the surface area increased. DFT energy for the RV-15 lead was lower than the RV-4 and RV-8t. There was no difference between energy requirements for the RV-15 and RV-8 leads. No difference was found in DFT current for each lead. Comparison of the RV-8t and RV-4 leads showed no difference in DFT energy despite a lower resistance and a greater number of edges. CONCLUSIONS: Increasing the RV TVL surface area lowered the resistance. However, surface area coverages > or = 40% did not lower DFT energy. No significant change in DFT current occurred despite different predicted near-field current densities. PDs were nearly identical 8 mm from the electrode surface. Thus, the far-field current density appears to play a more important role in determining defibrillation success.